One form of assisted reproductive technology-based fertility treatment used in clinical settings is in vitro fertilisation. Due to the fact that the likelihood of conceiving decreases with age, women who delay motherhood are a major driver driving the IVF industry. Those between the ages of 35 and 39 had a higher success percentage when using IVF to conceive.

Growing support for the spread of infertility clinics and services across Europe, a growing focus on fertility protection initiatives among market participants, and education targeted at fortifying the network for exchanging best practices and succinct information on infertility and fertility are some of the factors that are anticipated to propel the European IVF market. Europe has a large number of IVF clinics because of the continent's growing population and the rising trend of women deferring pregnancy. In addition, the probability of naturally becoming pregnant decreases with age, contributing to the increase in infertility cases. As a result, more women are forced to use banking services for in vitro fertilisation to raise the success rate, which is expected to drive market growth. Moreover, it is anticipated that the IVF sector will keep growing since these facilities strive to dispel the stigma associated with infertility by providing support for all forms of reproductive therapies.

Growing awareness of the array of infertility treatment options available is another factor contributing to the expansion of the European IVF market. Moreover, the market players' growing efforts to spread information about infertile centres and infertility treatment via social media and television help to disseminate knowledge about the cost and course of treatment, which encourages treatment adoption among low-income and rural residents.

However, it is anticipated that the expensive cost of IVF treatments combined with strict government regulations will impede the regional industry's rate of expansion. Moreover, a patient may need multiple pregnancy cycles due to the reduced success rate of IVF procedures, which increases the entire cost. This procedure usually costs between USD 15,125 and USD 25,300, which is a significant barrier to using the treatment. Two other barriers preventing the market from growing are the lack of reimbursement and moral dilemmas. Moreover, the lack of reimbursements and ethical concerns around IVF obstruct the growth of the European IVF industry.

Due to the COVID-19 pandemic, there were disruptions in the Europe in-vitro fertilisation (IVF) business. IVF treatments were hampered by lockdowns, travel restrictions, and healthcare system priorities. Delays and cancellations resulted from the temporary stoppage of fertility treatments and other non-essential medical services. Individuals were uncertain and hesitant to seek reproductive therapy. But when regulations relaxed, the market recovered and safety procedures were given more attention. The pandemic highlighted how crucial resilience and strategic planning are to the IVF sector.

The market study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as; Cadila Healthcare Ltd., DRK Kliniken Berlin, EMD Serono Inc., LG Life Sciences, Sun Pharmaceutical Industries Ltd., Thermo Fisher Scientific, Inc., Others.

By Cycle Type: Based on the Cycle Type, Europe In-Vitro Fertilization (IVF) Market is segmented as; Donor Egg IVF Cycle, Fresh Cycle (Non-Donor), Thawed IVF Cycle (Non-Donor).

By End User: Based on the End User, Europe In-Vitro Fertilization (IVF) Market is segmented as; Clinical Research Institutes, Fertility Clinics, Hospitals, Surgical Centers.

By Region: This research also includes data for Denmark, France, Germany, Italy, Russia, Spain, UK, Rest of Europe.

This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.